FcRn Inhibitors Play an Evolving Role in Myasthenia Gravis Treatment

(MedPage Today) — Three drugs that inhibit the immunoglobulin G (IgG) neonatal fragment crystallizable receptor (FcRn) were approved to treat generalized myasthenia gravis (MG) in recent years: efgartigimod (Vyvgart), rozanolixizumab (Rystiggo…